Intraoperative botulinum toxin injection for superficial partial parotidectomy: A prospective pilot study

xlomafota13 shared this article with you from Inoreader Intraoperative botulinum toxin injection for superficial partial parotidectomy: A prospective pilot study Via Clinical Otolaryngology Abstract Objectives Sialocele and salivary fistula are not serious but troublesome complications after parotidectomy. Various modalities have been introduced to prevent postoperative saliva‐related complications. However, clinical trials assessing the prophylactic use of botulinum toxin (BTX) for parotidectomy has not been conducted yet. Herein, we report a pilot study investigating the safety and efficacy of intraoperative BTX (iBTX) injection in partial superficial parotidectomy (PSP). Participants Patients with benign parotid tumor were prospectively recruited for this clinical trial from 2017 to 2019. The study participants underwent PSP with iBTX injection. We retrospectively reviewed the clinical information of all the consecutive patients who underwent PSP without iBTX from 2013 to 2019. These patients were divided into the two groups: the iBTX group (n = 36) and the control group (n = 54). Results Permanent facial palsy was not observed in either group. None had transient marginal palsy in the iBTX group but 2 patients (3.7%) had it in the control group. The incidence of sialocele was significantly lower in the iBTX group than in the control group (2.8% vs. 20.4%, P<0.05). Although the incidence of salivary fistula was lower in the iBTX group than in the control group (0% vs. 7.4%), no significant difference was determined between the two groups (P=0.147). Total drainage volume was significantly lower in the iBTX group than in the control group (55.0ml vs. 116.6ml, P<0.001). Conclusions iBTX injection may be safe and effective in reducing sialocele and postoperative drainage in PSP. It might be a useful option to prevent saliva‐related complication after PSP. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.